Vijay Samant

Direktor/Vorstandsmitglied bei

Xiconic Pharmaceuticals LLC

79 Jahre

88 Beziehungen

Health Technology

Commercial Services

Consumer Services

Profil

Vijay B. Samant currently works at Xiconic Pharmaceuticals LLC, as Director.
Mr. Samant also formerly worked at Vical, Inc., as President, Chief Executive Officer & Director from 2000 to 2019, AmpliPhi Biosciences Corp., as Independent Director from 2015 to 2019, Materials Management, Inc., as Executive Director, BioMarin Pharmaceutical, Inc., as Director from 2002 to 2004, Aeras Global TB Vaccine Foundation, as Director in 2010, Raptor Pharmaceuticals Corp., as Director from 2011 to 2014, Horizon Pharmaceutical LLC, as Independent Director from 2011 to 2014, Fresh Tracks Therapeutics, Inc., as Independent Director from 2000 to 2023, Merck & Co., Inc., as Chief Operating Officer-Vaccine Division from 1998 to 2000, National Foundation for Infectious Diseases, as Trustee from 2003 to 2012, and International Vaccine Institute, as Trustee from 2011 to 2012.
Mr. Samant received his graduate degree in 1977 from The Trustees of Columbia University in The City of New York, undergraduate degree in 1975 from the University of Mumbai, and Masters Business Admin degree in 1983 from MIT Sloan School of Management.

Aktive Positionen von Vijay Samant

Unternehmen	Position	Beginn
Xiconic Pharmaceuticals LLC Xiconic Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Founded in 2016, Xiconic Pharmaceuticals LLC is a biopharmaceutical company focused on developing cancer treatments. The company is based in Blue Bell, PA. The company advances a novel tumor antigen discovery—activated matriptase (actm)—which is predominantly expressed on tumor cells across multiple epithelial cancers and certain lymphomas. Xiconic's lead product, XCN-010 (matriptimab™-mmae), is a first-in-class antibody-drug conjugate that selectively targets actm using the M69 monoclonal antibody. XCN-010 employs proprietary pegylation technology to enhance linker stability, reduce off-target toxicity, and enable efficient intracellular release of the potent microtubule inhibitor monomethyl auristatin e (mmae), with a drug-antibody ratio accepted by the FDA. Preclinical studies demonstrate XCN-010’s potency and selectivity against actm-positive tumor cells in vitro and efficacy in multiple in vivo tumor models, including breast, non-small cell lung, prostate cancers, and mantle cell lymphoma. Combination therapy with olaparib further enhances antitumor effects without added toxicity. The company has licensed key intellectual property from Rutgers and Georgetown universities and is progressing toward clinical development.	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Vijay Samant

Ehemalige bekannte Positionen von Vijay Samant

Unternehmen	Position	Ende
FRESH TRACKS THERAPEUTICS, INC.	Direktor/Vorstandsmitglied	02.10.2023
Vical, Inc. Vical, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products	Vorstandsvorsitzender	01.08.2019
AmpliPhi Biosciences Corp. AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics	Direktor/Vorstandsmitglied	01.01.2019
RAPTOR PHARMACEUTICAL CORP	Direktor/Vorstandsmitglied	28.07.2014
Raptor Pharmaceuticals Corp. Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops drugs and drug-delivery platforms	Direktor/Vorstandsmitglied	01.01.2014

Sehen Sie sich die Erfahrung von Vijay Samant im Detail an

Ausbildung von Vijay Samant

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Vijay Samant im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	15
Merck & Co., Inc. Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines	Health Technology
Vical, Inc. Vical, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products	Health Technology
AmpliPhi Biosciences Corp. AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics	Health Technology
Materials Management, Inc. Materials Management, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in planning and management of precious metal assets	Commercial Services
BioMarin Pharmaceutical, Inc. BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions	Health Technology
Aeras Global TB Vaccine Foundation Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD.	Commercial Services
The Trustees of Columbia University in The City of New York The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Mumbai University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Raptor Pharmaceuticals Corp. Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops drugs and drug-delivery platforms	Health Technology
National Foundation for Infectious Diseases National Foundation for Infectious Diseases Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization	Commercial Services
International Vaccine Institute International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services Develops and distributes vaccines	Commercial Services
Horizon Pharmaceutical LLC Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of life-altering therapeutics that treat debilitating and often fatal diseases	Health Technology
MIT Sloan School of Management MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates pharmaceutical company that develops and manufactures prescription therapeutics products for the treatment of autoimmune, inflammatory and debilitating diseases	Health Technology
Xiconic Pharmaceuticals LLC Xiconic Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Founded in 2016, Xiconic Pharmaceuticals LLC is a biopharmaceutical company focused on developing cancer treatments. The company is based in Blue Bell, PA. The company advances a novel tumor antigen discovery—activated matriptase (actm)—which is predominantly expressed on tumor cells across multiple epithelial cancers and certain lymphomas. Xiconic's lead product, XCN-010 (matriptimab™-mmae), is a first-in-class antibody-drug conjugate that selectively targets actm using the M69 monoclonal antibody. XCN-010 employs proprietary pegylation technology to enhance linker stability, reduce off-target toxicity, and enable efficient intracellular release of the potent microtubule inhibitor monomethyl auristatin e (mmae), with a drug-antibody ratio accepted by the FDA. Preclinical studies demonstrate XCN-010’s potency and selectivity against actm-positive tumor cells in vitro and efficacy in multiple in vivo tumor models, including breast, non-small cell lung, prostate cancers, and mantle cell lymphoma. Combination therapy with olaparib further enhances antitumor effects without added toxicity. The company has licensed key intellectual property from Rutgers and Georgetown universities and is progressing toward clinical development.	Health Technology